Cat. No. | Product name | CAS No. |
DC20293 |
14-3-3 inhibitor BV2
A novel nonpeptidic inhibitor of 14-3-3 protein-protein interaction that promotes the apoptotic death of cells expressing either wt Bcr-Abl construct or T315I mutation. |
302602-92-2 |
DC11910 |
IPL-576092
A novel orally active, anti-inflammatory compound that inhibits leukocyte infiltration and changes in lung function in response to allergen challenge. |
202415-99-4 |
DC23994 |
Peretinoin
A novel orally available, synthetic retinoid with potential antineoplastic and chemopreventive activities. |
81485-25-8 |
DC24203 |
P2X2/3 receptor antagonist
Featured
A novel P2X3 and P2X2/3 receptor antagonist useful for the treatment of urinary tract diseases, pain, respiratory diseases and cardiovascular diseases. |
2310392-52-8 |
DC22434 |
POL5551
A novel peptidic, potent and highly selective CXCR4 antagonist with IC50 of 1.7 nM. |
1569304-29-5 |
DC3161 |
Prasugrel
Featured
A novel platelet inhibitor |
150322-43-3 |
DC23635 |
YM 758
A novel potent "funny" If current channel (If channel) inhibitor that inhibits rOct1- and hOCT1-mediated [3H]MPP uptake with IC50 of 23.8 and 40.5 uM, respectively. |
312752-86-6 |
DC23542 |
LY3031207
A novel potent (IC50=910 ng/mL), highly selective microsomal prostaglandin E synthase 1 inhibitor (mPGES-1) for treatment of undisclosed indications.. |
1381846-21-4 |
DC23841 |
EW-7195
Featured
A novel potent and selective TGF-βRI (ALK5) inhibitor with IC50 of 4.83 nM, dispalys >300-fold selectivity over p38α. |
1352609-28-9 |
DC22734 |
UR-1102
A novel potent and selective, orally active URAT1 inhibitor with Ki of 57 nM, 130 and 42-fold selectivity over OAT1 and OAT3, respectively. |
1198153-15-9 |
DC20826 |
BPR1K653 hydrochloride
A novel potent Aurora kinase inhibitor that inhibits Aurora-A and Aurora-B with IC50 of 24 nM and 45 nM, respectively. |
1192754-07-6 |
DC21048 |
GIV3727
A novel potent bitter receptor (TAS2Rs) antagonist that inhibits activation of hTAS2R31 by saccharin and acesulfame K with IC50 of 6.4 and 7.9 uM respectively. |
957136-80-0 |
DC20534 |
Revosimeline
A novel potent cannabinoid receptor agonist.. |
1810001-96-7 |
DC20435 |
Leucettine L41
A novel potent cdc2-like kinase (CLKs) and DYRKs inhibitor with IC50 of 40, 35 and 15 nM for DYRK1A, DYRK2 and CLK1, respectively. |
112978-84-3 |
DC21453 |
Riviciclib
A novel potent CDK inhibitor with IC50 of 79 nM, 63 nM and 20 nM for Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, respectively. |
920113-03-7 |
DC22743 |
OSSK-674842
A novel potent CFTR potentiator that blocks hCFTR with apparent Kd of 71.3 uM. |
2054944-80-6 |
DC22739 |
OSSK-630513
A novel potent CFTR potentiator with Kd of 31.7 nM. |
2054944-79-3 |
DC21855 |
ZINC 39395747
A novel potent derivative of propylthiouracil that functions as a cell-active inhibitor of cytochrome b5 reductase 3 (CYB5R3) with IC50 of 9.14 uM. |
1801163-44-9 |
DC20437 |
Linzagolix
A novel potent gonadotrophin releasing hormone (GnRH) antagonist.. |
935283-04-8 |
DC20482 |
Opigolix
A novel potent gonadotrophin releasing hormone (GnRH) antagonist.. |
912587-25-8 |
DC22861 |
CRT-0105950
A novel potent LIMK inhibitor with IC50 of 0.3 nM and 1 nM for LIMK1 and LIMK2, respectively. |
1661845-86-8 |
DC22862 |
CRT-0105446
A novel potent LIMK inhibitor with IC50 of 8 nM and 32 nM for LIMK1 and LIMK2, respectively. |
1661846-05-4 |